middle.news
Neurotech Secures $4.5 Million to Fund Pivotal Autism Trial
9:26am on Tuesday 4th of August, 2026 AEST
•
Healthcare
Read Story
Neurotech Secures $4.5 Million to Fund Pivotal Autism Trial
9:26am on Tuesday 4th of August, 2026 AEST
Key Points
Placement of 321 million shares at $0.014 each
Funding to cover Phase III ASD trial and regulatory costs
Tranche 1 settlement expected mid-August 2026
Tranche 2 subject to shareholder approval in September
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE